These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 33253391)

  • 1. Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis.
    Petrou P; Kassis I; Levin N; Paul F; Backner Y; Benoliel T; Oertel FC; Scheel M; Hallimi M; Yaghmour N; Hur TB; Ginzberg A; Levy Y; Abramsky O; Karussis D
    Brain; 2020 Dec; 143(12):3574-3588. PubMed ID: 33253391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intrathecal mesenchymal stem cell-neural progenitor therapy in progressive MS: results from a phase II, randomized, placebo-controlled clinical trial.
    Harris VK; Stark J; Williams A; Roche M; Malin M; Kumar A; Carlson AL; Kizilbash C; Wollowitz J; Andy C; Gerber LM; Sadiq SA
    Stem Cell Res Ther; 2024 May; 15(1):151. PubMed ID: 38783390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial.
    Uccelli A; Laroni A; Ali R; Battaglia MA; Blinkenberg M; Brundin L; Clanet M; Fernandez O; Marriot J; Muraro P; Nabavi SM; Oliveri RS; Radue E; Ramo Tello C; Schiavetti I; Sellner J; Sorensen PS; Sormani MP; Wuerfel JT; Freedman MS;
    Lancet Neurol; 2021 Nov; 20(11):917-929. PubMed ID: 34687636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal stem cells and conditioned media in the treatment of multiple sclerosis patients: Clinical, ophthalmological and radiological assessments of safety and efficacy.
    Dahbour S; Jamali F; Alhattab D; Al-Radaideh A; Ababneh O; Al-Ryalat N; Al-Bdour M; Hourani B; Msallam M; Rasheed M; Huneiti A; Bahou Y; Tarawneh E; Awidi A
    CNS Neurosci Ther; 2017 Nov; 23(11):866-874. PubMed ID: 28961381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical safety of intrathecal administration of mesenchymal stromal cell-derived neural progenitors in multiple sclerosis.
    Harris VK; Vyshkina T; Sadiq SA
    Cytotherapy; 2016 Dec; 18(12):1476-1482. PubMed ID: 27727015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis.
    Cohen JA; Imrey PB; Planchon SM; Bermel RA; Fisher E; Fox RJ; Bar-Or A; Sharp SL; Skaramagas TT; Jagodnik P; Karafa M; Morrison S; Reese Koc J; Gerson SL; Lazarus HM
    Mult Scler; 2018 Apr; 24(4):501-511. PubMed ID: 28381130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis.
    Petrou P; Kassis I; Ginzberg A; Hallimi M; Karussis D
    Stem Cells Transl Med; 2022 Mar; 11(1):55-58. PubMed ID: 35641166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesenchymal stem cell-derived neural progenitors in progressive MS: Two-year follow-up of a phase I study.
    Harris VK; Stark JW; Yang S; Zanker S; Tuddenham J; Sadiq SA
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33277427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
    Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
    Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Trial of Intrathecal Mesenchymal Stem Cell-derived Neural Progenitors in Progressive Multiple Sclerosis.
    Harris VK; Stark J; Vyshkina T; Blackshear L; Joo G; Stefanova V; Sara G; Sadiq SA
    EBioMedicine; 2018 Mar; 29():23-30. PubMed ID: 29449193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.
    Uccelli A; Laroni A; Brundin L; Clanet M; Fernandez O; Nabavi SM; Muraro PA; Oliveri RS; Radue EW; Sellner J; Soelberg Sorensen P; Sormani MP; Wuerfel JT; Battaglia MA; Freedman MS;
    Trials; 2019 May; 20(1):263. PubMed ID: 31072380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.
    Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA
    Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials.
    Petrou P; Gothelf Y; Argov Z; Gotkine M; Levy YS; Kassis I; Vaknin-Dembinsky A; Ben-Hur T; Offen D; Abramsky O; Melamed E; Karussis D
    JAMA Neurol; 2016 Mar; 73(3):337-44. PubMed ID: 26751635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.
    Llufriu S; Sepúlveda M; Blanco Y; Marín P; Moreno B; Berenguer J; Gabilondo I; Martínez-Heras E; Sola-Valls N; Arnaiz JA; Andreu EJ; Fernández B; Bullich S; Sánchez-Dalmau B; Graus F; Villoslada P; Saiz A
    PLoS One; 2014; 9(12):e113936. PubMed ID: 25436769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological efficacy and safety of mesenchymal stem cells (MSCs) therapy in people with multiple sclerosis (pwMS): An updated systematic review and meta-analysis.
    Vaheb S; Afshin S; Ghoshouni H; Ghaffary EM; Farzan M; Shaygannejad V; Thapa S; Zabeti A; Mirmosayyeb O
    Mult Scler Relat Disord; 2024 Jul; 87():105681. PubMed ID: 38838423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study.
    Connick P; Kolappan M; Crawley C; Webber DJ; Patani R; Michell AW; Du MQ; Luan SL; Altmann DR; Thompson AJ; Compston A; Scott MA; Miller DH; Chandran S
    Lancet Neurol; 2012 Feb; 11(2):150-6. PubMed ID: 22236384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.
    Bonab MM; Sahraian MA; Aghsaie A; Karvigh SA; Hosseinian SM; Nikbin B; Lotfi J; Khorramnia S; Motamed MR; Togha M; Harirchian MH; Moghadam NB; Alikhani K; Yadegari S; Jafarian S; Gheini MR
    Curr Stem Cell Res Ther; 2012 Nov; 7(6):407-14. PubMed ID: 23061813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis.
    Petrou P; Kassis I; Yaghmour NE; Ginzberg A; Karussis D
    Front Biosci (Landmark Ed); 2021 Oct; 26(10):693-706. PubMed ID: 34719198
    [No Abstract]   [Full Text] [Related]  

  • 19. Mesenchymal stem cell transplantation in multiple sclerosis.
    Cohen JA
    J Neurol Sci; 2013 Oct; 333(1-2):43-9. PubMed ID: 23294498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Patients With Heart Failure: A Phase 1/2 Randomized Controlled Trial (RIMECARD Trial [Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy]).
    Bartolucci J; Verdugo FJ; González PL; Larrea RE; Abarzua E; Goset C; Rojo P; Palma I; Lamich R; Pedreros PA; Valdivia G; Lopez VM; Nazzal C; Alcayaga-Miranda F; Cuenca J; Brobeck MJ; Patel AN; Figueroa FE; Khoury M
    Circ Res; 2017 Oct; 121(10):1192-1204. PubMed ID: 28974553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.